Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff J C, Bohrer M H, Riemann J F
Medizinische Klinik C, Klinikum Ludwigshafen gGmbH.
Dtsch Med Wochenschr. 2007 Feb 23;132(8):369-74. doi: 10.1055/s-2007-970342.
BACKGROUND AND OBJECTIVE: The diagnostic approach to newly detected space-occupying lesions in the liver can be difficult and a histogenetic classification of the primary tumor is impossible in some cases. Such cases of metastatic disease without a detectable primary tumor are classified as cancer of unknown primary site (CUP). The incidence of this diagnosis depends on the clinical and histochemical methods used. It was the main aim of this study to analyze the true incidence of adenocarcinoma metastases of the liver with an unknown primary cancer after application of a standardized protocol of clinical and immunhistochemical diagnostic tests and a long-term follow-up. PATIENTS AND METHODS: Between January 2000 and January 2003 127 consecutive patients underwent diagnostic ultrasound-guided biopsy of a space-occupying lesion in the liver. Based on the histopathology and immunochemistry a well defined and individually adapted diagnostic algorithm was employed (endoscopy, imaging). RESULTS: 44 females and 83 males, median age 66.8 years, were enrolled into the study. Primary tumors of the liver were found in 21 cases and non-hepatocellular tumors (metastases) were documented in 106 patients, 82 of the latter (77%) had metastases of an adenocarcinoma. The further diagnostic approach was based on histochemistry, immunhistochemistry and imaging techniques, making possible a full diagnosis of primary tumor in a further 59 (72%) cases. Thus the incidence of an adenocarcinoma of the liver of unknown primary site was 23 of 127 cases (18%). CONCLUSIONS: Although there is a wide variety of modern diagnostic methods today, the histogenetic classification of hepatic metastases is not always possible. However, in the last few years diagnostic advances have occurred based on modern immunhistochemical methods. This immunhistochemical definition has made it possible to avoid an oppressive "overdiagnosis" and offer patients early and appropriate therapeutic options.
背景与目的:对于新发现的肝脏占位性病变,其诊断方法可能具有挑战性,在某些情况下无法对原发性肿瘤进行组织发生学分类。这类无法检测到原发性肿瘤的转移性疾病病例被归类为原发部位不明的癌症(CUP)。这种诊断的发生率取决于所使用的临床和组织化学方法。本研究的主要目的是,在应用标准化的临床和免疫组织化学诊断测试方案并进行长期随访后,分析原发性癌症不明的肝脏腺癌转移的真实发生率。 患者与方法:2000年1月至2003年1月期间,127例连续患者接受了肝脏占位性病变的诊断性超声引导下活检。基于组织病理学和免疫化学,采用了明确且个体化的诊断算法(内镜检查、影像学检查)。 结果:44名女性和83名男性,中位年龄66.8岁,纳入本研究。21例发现肝脏原发性肿瘤,106例记录为非肝细胞性肿瘤(转移瘤),其中82例(77%)为腺癌转移。进一步的诊断方法基于组织化学、免疫组织化学和影像学技术,使得另外59例(72%)能够完全诊断出原发性肿瘤。因此,原发部位不明的肝脏腺癌发生率为127例中的23例(18%)。 结论:尽管如今有各种各样的现代诊断方法,但肝转移瘤的组织发生学分类并非总是可行。然而,在过去几年中,基于现代免疫组织化学方法取得了诊断进展。这种免疫组织化学定义使得避免压迫性的“过度诊断”成为可能,并为患者提供早期且合适的治疗选择。
Dtsch Med Wochenschr. 2007-2-23
Rev Med Chir Soc Med Nat Iasi. 2003
Magn Reson Imaging. 2003-10
Z Gastroenterol. 2005-10
J Ayub Med Coll Abbottabad. 2014
Mymensingh Med J. 2004-1
J Clin Oncol. 1998-6